r-428

Small moleculeexperimental

Clinical trial activity

4 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2014 (NCT02488408)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1nc(Nc2ccc3c(c2)CCC(N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2
Mol. weight
506.66 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bgb324
  • bgb324
  • bgb-324
  • bgb-324
  • cs-1046
  • cs-1046
  • hy-15150
  • hy-15150
  • kb-80319
  • kb-80319
  • qc-11751
  • qc-11751
  • r428
  • r428
  • r-428
  • r-428
  • r-428
  • syn-1131
  • syn-1131
  • w-5845
  • w-5845

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02872259Phase 1/Phase 2 (Phase 2)Jan 1, 2017BerGenBio ASA, University of Bergen
NCT02922777Phase 1Nov 1, 2016BerGenBio ASA, Texas Tech University, The University of Texas, Dallas
NCT02424617Phase 1/Phase 2 (Phase 2)Mar 1, 2015BerGenBio ASA, Chiltern International, University of Texas at Houston
NCT02488408Phase 1/Phase 2 (Phase 2)Sep 1, 2014BerGenBio ASA, University of Hamburg
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BerGenBio ASAFor profit4222014
Chiltern InternationalFor profit1012015
Texas Tech UniversityAcademic/Hospital1012016
The University of Texas, DallasAcademic/Hospital1112016
University of BergenAcademic/Hospital1112017
University of HamburgAcademic/Hospital1012014
University of Texas at HoustonAcademic/Hospital1012015
7 organizations
Page 1 / 1